schizophrenia
Conditions
Interventions
Group of Paliperidone Palmitate:Injection of paliperidone palmitate injection
Sponsors
Henan Mental Hospital,The Second Affiliated Hospital of Xinxiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: (1) Outpatients or inpatients with schizophrenia who met the ICD-10 diagnostic criteria; (2) patients in the acute or stable phase of the disease; (3) Both male and female, aged 18-65 years old (4) Written informed consent was obtained from the patient and legal guardian, and written informed consent was obtained from the legal guardian if the patient had no insight during the onset.
Exclusion criteria
Exclusion criteria: Exclusion criteria: (1) Individuals with schizophrenia, mood disorders, mental retardation, pervasive developmental disorders, delirium, dementia, memory impairment, or other cognitive impairments that meet the diagnostic criteria of ICD-10; (2) Mental disorders caused by substance abuse (alcohol, drugs, etc.), people with serious unstable physical diseases, diagnosed diabetes, thyroid disease, hypertension, heart disease, etc; (3) Narrow angle glaucoma; (4) patients with a history of epilepsy (except febrile convulsions); (5) Patients who met the diagnostic criteria of ICD-10-TR for alcohol and drug dependence (except nicotine dependence); (6) Patients who suffer from or have previously suffered from drug-induced malignant syndrome and severe late-onset motor disorders; (7) Patients with significant abnormal laboratory results (AST or ALT= 2 times of the upper limit of normal; BUN= 1.5 times the upper limit of normal; Cr= 1.2 times the upper limit of normal); (8) Unable to follow the doctor's advice, or without a guardian; (9) QTc interval prolongation (QTc=450 ms in men or =470 ms in women); (10) Pregnant or lactating women, or those planning to become pregnant; (11) Patients with contraindications to antipsychotic drugs recommended in this study; (12) Other conditions considered by the investigators to be inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy;Laboratory Examinations; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety; | — |
Countries
China
Contacts
Public ContactJingyuan Zhao
Henan Mental Hospital,The Second Affiliated Hospital of Xinxiang Medical University
Outcome results
None listed